BioMarin vets spearhead new biotech with $82M for rare disease drugs
百迈生物制药资深人士领衔创立新生物技术公司，获8200万美元融资用于罕见病药物研发

A fresh biotech has raised $82 million to scour the landscape of rare disease medicines that need a new home for further development and apply lessons from executives’ experiences at BioMarin.
一家新成立的生物技术公司筹集了8200万美元，旨在梳理罕见病药物版图，寻找那些需要“新归宿”以继续开发的项目，并借鉴高管在百迈生物制药的经验教训。